Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

USA - NASDAQ:XLO - US98422T1007 - Common Stock

0.7528 USD
0 (-0.34%)
Last: 10/22/2025, 8:09:12 PM
0.7422 USD
-0.01 (-1.41%)
After Hours: 10/22/2025, 8:09:12 PM
Fundamental Rating

2

Taking everything into account, XLO scores 2 out of 10 in our fundamental rating. XLO was compared to 534 industry peers in the Biotechnology industry. XLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.
In the past year XLO has reported a negative cash flow from operations.
XLO had negative earnings in each of the past 5 years.
XLO had a negative operating cash flow in each of the past 5 years.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

XLO's Return On Assets of -42.02% is in line compared to the rest of the industry. XLO outperforms 57.12% of its industry peers.
XLO has a Return On Equity of -795.33%. This is amonst the worse of the industry: XLO underperforms 80.34% of its industry peers.
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

XLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
XLO has more shares outstanding than it did 1 year ago.
XLO has more shares outstanding than it did 5 years ago.
XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.79, we must say that XLO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.79, XLO is doing worse than 60.49% of the companies in the same industry.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.79
ROIC/WACCN/A
WACC9.23%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.32 indicates that XLO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.32, XLO is doing worse than 70.60% of the companies in the same industry.
A Quick Ratio of 2.32 indicates that XLO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.32, XLO is doing worse than 68.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.32
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.98% over the past year.
Looking at the last year, XLO shows a very strong growth in Revenue. The Revenue has grown by 536.44%.
EPS 1Y (TTM)63.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)536.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%242.98%

3.2 Future

The Earnings Per Share is expected to grow by 18.00% on average over the next years. This is quite good.
XLO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -19.00% yearly.
EPS Next Y64.49%
EPS Next 2Y32.34%
EPS Next 3Y13.84%
EPS Next 5Y18%
Revenue Next Year405.45%
Revenue Next 2Y170.33%
Revenue Next 3Y27.92%
Revenue Next 5Y-19%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M 40M 50M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as XLO's earnings are expected to grow with 13.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.34%
EPS Next 3Y13.84%

More info and screens

0

5. Dividend

5.1 Amount

XLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (10/22/2025, 8:09:12 PM)

After market: 0.7422 -0.01 (-1.41%)

0.7528

0 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners25.42%
Inst Owner Change0%
Ins Owners0.75%
Ins Owner Change0.78%
Market Cap39.02M
Revenue(TTM)15.00M
Net Income(TTM)-56222000
Analysts83.33
Price Target2.04 (170.99%)
Short Float %17.57%
Short Ratio7.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-192.81%
Min EPS beat(2)-287.6%
Max EPS beat(2)-98.02%
EPS beat(4)2
Avg EPS beat(4)-91.33%
Min EPS beat(4)-287.6%
Max EPS beat(4)11.7%
EPS beat(8)4
Avg EPS beat(8)-100.06%
EPS beat(12)7
Avg EPS beat(12)-63.15%
EPS beat(16)9
Avg EPS beat(16)-122.29%
Revenue beat(2)0
Avg Revenue beat(2)-18.29%
Min Revenue beat(2)-34.07%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-29.24%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)-2.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)81.25%
EPS NY rev (1m)-190.32%
EPS NY rev (3m)26.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)151.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)54.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 5.52
P/tB 5.52
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.29
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.81%
Cap/Sales 2.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 2.32
Altman-Z -4.79
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y64.49%
EPS Next 2Y32.34%
EPS Next 3Y13.84%
EPS Next 5Y18%
Revenue 1Y (TTM)536.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%242.98%
Revenue Next Year405.45%
Revenue Next 2Y170.33%
Revenue Next 3Y27.92%
Revenue Next 5Y-19%
EBIT growth 1Y15.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y83.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.33%
OCF growth 3YN/A
OCF growth 5YN/A